跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
醫學系內科學科
醫學院
醫學系
概覽
指紋
網路
人員
(16)
研究成果
(3028)
獎項
(27)
活動
(85)
指紋
查看啟用 醫學系內科學科 的研究主題。這些主題標籤來自此機構會員的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Taiwan
100%
Atrial Fibrillation
85%
Catheter Ablation
49%
Hepatocellular Carcinoma
46%
Confidence Interval
40%
Hazard Ratio
33%
Clinical Outcomes
32%
Hypertension
29%
Risk Factors
27%
Atrial Fibrillation Ablation
24%
Heart Failure
23%
National Cohort Study
22%
Paroxysmal Atrial Fibrillation
22%
Ablation
22%
Blood Pressure
20%
Ventricular Arrhythmia
20%
Hemodialysis Patients
19%
Taiwanese
17%
All-cause Mortality
17%
Asia
16%
Cirrhosis
16%
Cardiovascular Mortality
15%
High Risk
15%
Type 2 Diabetes Mellitus (T2DM)
15%
Odds Ratio
15%
Hypertension Management
14%
Chronic Kidney Disease
14%
Multivariate Analysis
14%
Overall Survival
14%
Pulmonary Vein Isolation
14%
Pulmonary Vein
14%
Prognostic Factors
13%
Atrial Substrate
13%
Meta-analysis
13%
Ca2+
13%
Left Atrium
13%
Systolic Blood Pressure
13%
Type 2 Diabetic Patients
12%
Portal Hypertension
12%
Southern Taiwan
12%
Heart Failure with Preserved Ejection Fraction (HFpEF)
11%
Systemic Lupus Erythematosus
11%
Cardiovascular Risk
11%
Liver Cirrhosis
11%
Taiwan Society of Cardiology
11%
Rheumatoid Arthritis
11%
Atrial Fibrillation Recurrence
11%
End-stage Renal Disease
11%
Type 1 Diabetes Mellitus (T1DM)
11%
Persistent Atrial Fibrillation
11%
Left Ventricular Ejection Fraction
10%
Randomized Controlled Trial
10%
Hemodialysis
10%
Clinical Characteristics
10%
Electrophysiological Characteristics
10%
Radiofrequency Ablation
10%
Liver
10%
Hepatocellular Carcinoma Patients
9%
CHA2DS2-VASc Score
9%
Central Blood Pressure
9%
Metabolic Syndrome
9%
Left Atrial
9%
Systematic Meta-analysis
9%
Diabetes
9%
Cirrhotic Patients
9%
Body Mass Index
9%
Clinical Significance
8%
General Hospital
8%
Chemotherapy
8%
SHP-1
8%
Induced Apoptosis
8%
Coronary Artery Disease
8%
Patients with Heart Failure
8%
Cardiovascular Disease
8%
COVID-19
8%
Percutaneous Coronary Intervention
8%
Ventricular Tachycardia
8%
Low Risk
8%
Acute Heart Failure
8%
Comorbidity
8%
Asian Patients
8%
High Incidence
8%
Medical Center
8%
Sinus Rhythm
7%
Apoptosis
7%
Intensive Care Unit
7%
Des-acyl Ghrelin
7%
Cardiovascular Events
7%
Tumor Necrosis Factor-α
7%
Taipei
7%
Sacubitril-valsartan
7%
Acute Respiratory Distress Syndrome
7%
Major Adverse Cardiovascular Events
7%
Electrogram
7%
Stroke Risk
7%
Myocardial Infarction
7%
Arrhythmogenic Right Ventricular Cardiomyopathy
7%
Portal Hypertensive
7%
Maintenance Hemodialysis Patients
7%
Portal Pressure
7%
Medicine and Dentistry
Atrial Fibrillation
79%
Ablation
53%
Hepatocellular Carcinoma
44%
Blood Pressure
36%
Cardiovascular System
30%
Congestive Heart Failure
29%
Diseases
26%
Recurrent Disease
26%
Hazard Ratio
26%
Cohort Analysis
25%
Liver Cirrhosis
24%
Apoplexy
23%
Prevalence
21%
Paroxysmal Atrial Fibrillation
19%
Hemodialysis
18%
Neoplasm
17%
Ventricular Tachycardia
16%
Cardiovascular Disease
15%
Pulmonary Vein
15%
Hemodynamic
15%
Pulmonary Vein Isolation
14%
Systolic Blood Pressure
14%
Chronic Kidney Disease
14%
Infection
13%
Diabetes Mellitus
13%
Cardiology
13%
Overall Survival
13%
Heart Ventricle Arrhythmia
13%
Maturity Onset Diabetes of the Young
12%
End Stage Renal Disease
12%
Pulse Wave Velocity
12%
Left Atrium
12%
Electrography
11%
Coronary Artery Disease
11%
Prognostic Factor
11%
Proportional Hazards Model
11%
Breast Cancer
11%
Odds Ratio
11%
Meta-Analysis
10%
Diabetes
10%
Multivariate Analysis
10%
All Cause Mortality
10%
Arrhythmogenic Right Ventricular Dysplasia
10%
Cardiovascular Risk
10%
COVID-19
9%
Portal Hypertension
9%
Systemic Lupus Erythematosus
9%
Antithrombotic
9%
Malignant Neoplasm
9%
Randomized Controlled Trial
9%
Heart Left Ventricle Ejection Fraction
8%
Atrial Fibrillation Ablation
8%
Intensive Care Unit
8%
Supraventricular Tachycardia
8%
Radiofrequency Ablation
8%
Persistent Atrial Fibrillation
8%
Observational Study
8%
Platelet
8%
Systematic Review
7%
Adverse Event
7%
Hepatitis B Virus
7%
Kidney Function
7%
Myocardial Disease
7%
Blood Pressure Monitoring
7%
Peritoneal Dialysis
7%
Transcatheter Arterial Chemoembolization
7%
Rheumatoid Arthritis
7%
Inflammatory Arthritis
7%
Body Mass Index
7%
CHA2DS2-VASc Score
7%
Surgery
7%
Atrial Flutter
7%
Acute Decompensated Heart Failure
7%
Ablation Therapy
7%
Electrocardiogram
7%
Sinus Rhythm
7%
Ejection Fraction
7%
Angiogenesis
7%
Bilirubin
7%
Brain Ischemia
7%
Heart Failure with Reduced Ejection Fraction
7%
Retrospective Study
7%
Percutaneous Coronary Intervention
7%
Diagnosis
6%
Human Immunodeficiency Virus
6%
Mortality Rate
6%
Patient with Type 2 Diabetes
6%
Myocardial Infarction
6%
Tumor Necrosis Factor
6%
Risk Stratification
6%
Bleeding
6%
Fibrosis
6%
Cancer
6%
Cardiovascular Mortality
6%
C Reactive Protein
6%
Biological Marker
6%
Elderly Patient
6%
Comorbidity
6%
Sudden Cardiac Death
6%
Acute Respiratory Distress Syndrome
6%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
56%
Liver Cell Carcinoma
52%
Congestive Heart Failure
33%
Diseases
32%
Cohort Study
32%
Prevalence
22%
Hemodialysis
22%
Recurrent Disease
21%
Cerebrovascular Accident
20%
Liver Cirrhosis
19%
Cardiovascular Disease
18%
Infection
16%
Neoplasm
14%
Overall Survival
14%
Chronic Kidney Failure
14%
Diabetes Mellitus
14%
All Cause Mortality
14%
Non Insulin Dependent Diabetes Mellitus
12%
Hepatitis B Virus
12%
Adverse Event
12%
Calcium Ion
11%
Rheumatoid Arthritis
11%
Inflammatory Arthritis
11%
Heart Ventricle Arrhythmia
11%
Chemotherapy
11%
End Stage Renal Disease
11%
Paroxysmal Atrial Fibrillation
11%
Coronary Artery Disease
11%
Breast Cancer
11%
Inflammation
10%
Randomized Controlled Trial
10%
Anticoagulant Agent
10%
Malignant Neoplasm
10%
Observational Study
9%
Portal Hypertension
9%
Colorectal Carcinoma
9%
Sorafenib
8%
Heart Right Ventricle Dysplasia
8%
Tumor Necrosis Factor
8%
Nonalcoholic Fatty Liver
8%
Combination Therapy
8%
Heart Ventricle Tachycardia
8%
Metabolic Syndrome X
8%
Creatinine
7%
Cardiovascular Risk
7%
Heart Failure with Reduced Ejection Fraction
7%
Comorbidity
7%
Bilirubin
7%
Myocardial Disease
7%
C Reactive Protein
7%
Valsartan/Sacubitril
7%
Brain Ischemia
7%
Chronic Hepatitis B
7%
Immune Checkpoint Inhibitor
7%
Systemic Lupus Erythematosus
7%
Syndrome
7%
HIV
6%
Progression Free Survival
6%
Remission
6%
Mortality Rate
6%
Heart Arrhythmia
6%
Cytokine
6%
Heart Infarction
6%
Retrospective Study
5%
Kidney Disease
5%
Adult Respiratory Distress Syndrome
5%
Cardiovascular Mortality
5%
Biological Marker
5%
Carbapenem
5%
Hepatitis B
5%
Placebo
5%
Coronavirinae
5%
Warfarin
5%
Immunotherapy
5%
Antihypertensive Agent
5%
Fibrosis
5%
Receptor
5%
Chronic Hepatitis C
5%
Arteriovenous Fistula
5%
Ghrelin
5%
Chronic Obstructive Lung Disease
5%
Rituximab
5%